What drugs does VIIV HLTHCARE make?

VIIV HLTHCARE has 19 FDA-approved drugs including TRIUMEQ PD, CABENUVA KIT, TIVICAY PD.

What therapeutic areas does VIIV HLTHCARE focus on?

VIIV HLTHCARE focuses primarily on Infectious Disease and Immunology.

← Back

Data updated: Mar 10, 2026

VIIV HLTHCARE

Infectious DiseaseImmunology

Biotech

VIIV HLTHCARE is a biotechnology company focused on Infectious Disease, Immunology. Key products include TRIUMEQ.

1987

Since

Drugs

Trials

Approved (2yr)

Key Drugs

Recent Activity

CABENUVA KIT 2025-11-26

Labeling

TRIUMEQ PD 2025-10-28

Labeling

TIVICAY PD 2025-10-28

CABENUVA KIT 2025-04-11

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 65%

11 drugs

Immunology 35%

6 drugs

Pipeline Strength ProEarly access

Competitors ProEarly access

Pfizer big-pharma

Infectious Disease, Immunology

Merck big-pharma

Infectious Disease, Immunology

AbbVie big-pharma

Immunology, Infectious Disease

Johnson & Johnson big-pharma

Immunology, Infectious Disease

GSK big-pharma

Infectious Disease, Immunology

VIIV HLTHCARE

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (19)

Active (13)

Discontinued (5)

Company Info